18F-FDG PET预测局部晚期非小细胞肺癌根治性放化疗后的失败模式
BACKGROUND: We previously reported that pretreatment positron emission tomography (PET) identifies lesions at high risk for progression after concurrent chemoradiation therapy (CRT) for locally advanced non-small cell lung cancer (NSCLC).…
要点
- 治疗前FDG-PET可识别放化疗后高进展风险的病灶。
- MTV>25 cc病灶30个月累积进展发生率23%,≤25 cc为4%。
- 未发现放疗剂量与局部进展风险相关。
核心结论
- 治疗前FDG-PET可识别局部晚期NSCLC根治性放化疗后进展风险高的病灶。
- 应针对高风险病灶测试提高局部控制的策略,并探索低风险病灶的治疗降强度。
主要发现
- 20例患者首次进展部位为接受放疗的原发肿瘤或淋巴结,中位进展时间11.5个月。
- 验证队列证实病灶MTV预测局部进展,>25 cc病灶30个月累积进展发生率为23%,≤25 cc为4%(P=.008)。
- 未发现放疗剂量与局部进展风险相关的证据。
- TCP模型预测30个月局部控制率:1 cc病灶98%,10 cc病灶94%,50 cc病灶74%。
临床怎么用
- 可利用治疗前FDG-PET测量的MTV识别高危病灶,指导局部控制策略的测试。
- 对低风险病灶可探索治疗降强度,但需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We previously reported that pretreatment positron emission tomography (PET) identifies lesions at high risk for progression after concurrent chemoradiation therapy (CRT) for locally advanced non-small cell lung cancer (NSCLC). Here we validate those findings and generate tumor control probability (TCP) models. METHODS: We identified patients treated with definitive, concurrent CRT for locally advanced NSCLC who underwent staging 18F-fluorodeoxyglucose/PET/computed tomography. Visible hypermetabolic lesions (primary tumors and lymph nodes) were delineated on each patient's pretreatment PET scan. Posttreatment imaging was reviewed to identify locations of disease progression. Competing risks analyses were performed to examine metabolic tumor volume (MTV) and radiation therapy dose as predictors of local disease progression. TCP modeling was performed to describe the likelihood of local disease control as a function of lesion size. RESULTS: Eighty-nine patients with 259 hypermetabolic lesions (83 primary tumors and 176 regional lymph nodes) met the inclusion criteria. Twenty-eight patients were included in our previous report, and the remaining 61 constituted our validation cohort. The median follow-up time was 22.7 months for living patients. In 20 patients, the first site of progression was a primary tumor or lymph node treated with radiation therapy. The median time to progression for those patients was 11.5 months. Data from our validation cohort confirmed that lesion MTV predicts local progression, with a 30-month cumulative incidence rate of 23% for lesions above 25 cc compared with 4% for lesions below 25 cc (P=.008). We found no evidence that radiation therapy dose was associated with local progression risk. TCP modeling yielded predicted 30-month local control rates of 98% for a 1-cc lesion, 94% for a 10-cc lesion, and 74% for a 50-cc lesion. CONCLUSION: Pretreatment FDG-PET identifies lesions at risk for progression after CRT for locally advanced NSCLC. Strategies to improve local control should be tested on high-risk lesions, and treatment deintensification for low-risk lesions should be explored.
引用
- Ohri N, Bodner WR, Halmos B, et al. 18F-Fluorodeoxyglucose/Positron Emission Tomography Predicts Patterns of Failure After Definitive Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2016. PMID: 28068244. doi:10.1016/j.ijrobp.2016.10.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。